博士眼鏡(300622.SZ):公司致力於智能眼鏡"最後一公里"的驗配業務和產品交付服務
格隆匯1月5日丨博士眼鏡(300622.SZ)接受特定對象調研時表示,公司致力於智能眼鏡"最後一公里"的驗配業務和產品交付服務,具體優勢如下:
(1)公司於兩年前積極佈局智能眼鏡賽道,並通過投資等方式扶持了相關智能眼鏡主機商,具有先發優勢;
(2)目前公司已與業內頭部智能眼鏡品牌雷鳥創新、ROKID、魅族建立獨家合作關係,具有排他性優勢;
(3)公司擁有全國連鎖品牌的渠道優勢,並通過定製化驗光配鏡服務、線上線下聯動售後服務為智能眼鏡的消費羣體提供視力矯正綜合解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.